Ic Mpgn clinical trials

Explore recruiting ic mpgn clinical trials.

Recruiting ic mpgn studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Ic Mpgn trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

An Open-Label, Randomized, Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of Pegcetacoplan in the Treatment of Post-Transplant Recurrence of C3G or IC‑MPGN

Netherlands, Austria, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in idiopathic immune complex mediated membranoproliferative glomerulonephritis (IC-MPGN)

France, Spain, Czechia, Germany, Italy, Poland +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Randomized, Placebo-Controlled, Double-Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients with C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis

Austria, Netherlands, Italy, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

An open-label, non-randomized extension study to evaluate the long-term efficacy, safety and tolerability of LNP023 in subjects with C3 glomerulopathy or idiopathic immune-complex-membranoproliferative glomerulonephritis

Germany, France, Czechia, Netherlands, Greece, Italy +1 more

Phase III and phase IV (Integrated) EU CTIS Study details

Real-World Effectiveness and Safety of Pegcetacoplan in Patients with C3 Glomerulopathy (C3G) or Primary Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN): A Multi-Country Study (PRISMC3)

France, Italy, Spain, Germany

Therapeutic use (Phase IV) EU CTIS Study details

An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis (VALE)

Spain, Italy, Czechia, France, Netherlands, Belgium +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Ic Mpgn trials by city

Ic Mpgn in Toronto Ic Mpgn in Vancouver Ic Mpgn in Montreal Ic Mpgn in Calgary Ic Mpgn in Edmonton Ic Mpgn in Ottawa Ic Mpgn in Winnipeg Ic Mpgn in Quebec City Ic Mpgn in Hamilton Ic Mpgn in Kitchener Ic Mpgn in London Ic Mpgn in Halifax Ic Mpgn in New York Ic Mpgn in Los Angeles Ic Mpgn in Chicago Ic Mpgn in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease